We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Equity Crowdfunding » Medical

Investment Opportunity: Quvium - Equity Crowdfunding

Status: Expired

Please watch the video for more information

read more read less
Visit Pitch at Syndicate Room More about Syndicate Room

Funding progress



More from Medical

Accunea is the world’s first real-time continuous organ function monitoring company, specializing in biomarkers for kidney transplantation. Targeting NHS hospitals in the UK undertaking renal transplantation, the company aims to provide relief to patients awaiting organ transplants by ensuring availability of more organs for transplant and reducing the numbers of deaths due to increasing waiting list times. For this purpose, the company has designed a miniature analysis device which constantly monitors markers of kidney function and metabolism through a standard dribble line put into the vein of a patient. Accunea is raising £400,000 at a pre-money valuation of £2,230,000. The funds will be used to achieve clinical utility in Kidney and Pancreas.

Pitch Rated

71%

Overall

rating powered by

CROWD RATING™

pledged: 59% days to go: 42 investment: £235,549
International Ambulances (IA) aims to save lives and to provide better outcomes for patients, paramedics and hospitals. The company is building a revolutionary ambulance the 'ACESO' that will be the first ever purpose built global ambulance. ACESO will address known challenges of accident & emergency departments and promote the NHS 'See and Treat' strategy. Of the ambulance fleet size of 14,000, International Ambulances (IA) has identified about 1,200 A&E Ambulances of which the opportunity for ACESO is 500 per year. 
pledged: 25% days to go: TBC investment: £251,600
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
pledged: 0% days to go: 2 investment: Unknown
AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
pledged: 66% days to go: TBC investment: £1,057,006

  • £257,501
    pledged
  • 52%
    of goal
  • Expired
    22 Jun 2015

    £500,000
    target

    £4,045,455
    pre-money valuation

    11.00%
    equity available

    7
    investors

    £36,786
    pledge per investor

    08715069
    company number

    Equity Calculator
    Investment
    £
    Equity
    %
    Funding rounds
    27 May 15 Syndicate Room £257,501 / 52%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph